SVR rates in recent DAA combination trials are really impressive. Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies. This Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?
It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick Continue reading 2014: The Year That Changed The Landscape of HCV Therapy
It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and Continue reading Snapshot: HCV Drugs in Development